ABSTRACT: Visual analogue scales are widely used to measure subjective responses. Norris' 16 visual analogue scales (N_VAS) measure subjective feelings of alertness and mood. Up to now, different scientists have clustered items of N_VAS into different ways and Bond and Lader's way has been the most frequently used in clinical research. However, there are concerns about the stability of this clustering over different subject samples and different drug classes. The aim of this study was to test whether Bond and Lader's clustering was stable in terms of subject samples and drug effects. Alternative clustering of N_VAS was tested.Data from studies with 3 types of drugs: cannabinoid receptor agonist (delta-9-tetrahydrocannabinol [THC]), muscarinic antagonist (scopolamine), and benzodiazepines (midazolam and lorazepam), collected between 2005 and 2012, were used for this analysis. Exploratory factor analysis (EFA) was used to test the clustering algorithm of Bond and Lader. Consensus clustering was performed to test the stability of clustering results over samples and over different drug types. Stability analysis was performed using a three-cluster assumption, and then on other alternative assumptions.Heat maps of the consensus matrix (CM) and density plots showed instability of the three-cluster hypothesis and suggested instability over the 3 drug classes. Two- and four-cluster hypothesis were also tested. Heat maps of the CM and density plots suggested that the two-cluster assumption was superior.In summary, the two-cluster assumption leads to a provably stable outcome over samples and the 3 drug types based on the data used.
References
Kola I, Landis J. Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov 2004;3:711–5.
Talevi A, Bellera CL, Di Ianni M, et al. CNS drug development – lost in translation? Mini Rev Med Chem 2012;12:959–70.
Bond AJ, Lader MH. Residual effects of hypnotics. Psychopharmacologia 1972;25:117–32.
Jarvis MJ, Lader MH. The effects of nitrous oxide on the auditory evoked response in a reaction time task. Psychopharmacologia 1971;20:201–12.
Mathew H, Proudfoot A, Atiken R, et al. Nitrazepam: a safe hypnotic. Br Med J 1969;3:23–5.
Montagu JD. Effects of quinalbarbitone (secobarbital) and nitrazepam on the EEG in man: quantitative investigations. Eur J Pharmacol 1971;14:238–49.
Norris H. The action of sedatives on brain stem oculomotor systems in man. Neuropharmacology 1971;10:181–91.
Malpas JF. The use of chlorine for water disinfection in industry. Chem Ind 1971;4:111–5.
Breivik EK, Bjørnsson GA, Skovlund E. A comparison of pain rating scales by sampling from clinical data. Clin J Pain 2000;16:22–8.
Hawker GA, Mian S, Kendzerska T, et al. Measures of adult pain: Visual Analog Scale for pain (VAS pain), Numeric Rating Scale for pain (NRS pain), Mcgill Pain Questionnaire (MPQ), Short-Form Mcgill Pain Questionnaire (SF-MPQ), Chronic Pain Grade Scale (CPGS), Short Form-36 Bodily Pain Scale (SF-36 BPS), and measure of Intermittent and Constant Osteoarthritis Pain (ICOAP). Arthritis Care Res 2011;63:S240–52.
Heller GZ, Manuguerr M, Chow R. How to analyze the visual analogue scale: myths, truths and clinical relevance. Scand J Pain 2016;13:67–75.
Sung Y, Wu J. The visual analogue scale for rating, ranking and paired-comparison (VAS-RRP): a new technique for psychological measurement. Behav Res Methods 2018;50:1694–715.
Brown A. Item response models for forced-choice questionnaires: a common framework. Psychometrika 2014;81:01–26.
Academic Press, Sajatovic M, Chen P, Young RC. Rating Scales in Bipolar Disorder, Clinical Trial Design Challenges in Mood Disorders. 1st ed2015.
Dauphin AP, Guillemin F, Virion JM, et al. Bias and precision in visual analogue scales: a randomized controlled trial. Am J Epidemiol 1999;150:1117–27.
Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974;47:211–8.
Herbert M, Johns MW, Doré C. Factor analysis of analogue scales measuring sugjective feelings before and after sleep. Br J Med Psychol 1976;49:373–9.
van der Post JP, de Visser SJ, Schoemaker RC, et al. Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients. J Psychopharmacol 2004;18:221–7.
Liem-Moolenaar M, Gray FA, de Visser SJ, et al. Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol. J Psychopharmacol 2010;24:73–82.
Liem-Moolenaar M, Zoethout RW, de Boer P, et al. The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects. J Psychopharmacol 2010;24:1671–9.
Liem-Moolenaar M, Zoethout RW, de Boer P, et al. The effects of a glycine reuptake inhibitor R231857 on the central nervous system and on scopolamine-induced impairments in cognitive and psychomotor function in healthy subjects. J Psychopharmacol 2010;24:1681–7.
Liem-Moolenaar M, te Beek ET, de Kam ML, et al. Central nervous system effects of haloperidol on THC in healthy male volunteers. J Psychopharmacol 2010;24:1697–708.
Kleinloog D, Roozen F, De Winter W, et al. Profiling the subjective effects of delta9-tetrahydrocannabinol using visual analogue scales. Int J Methods Psychiatr Res 2014;23:245–56.
Muehlan C, Zuiker R, Peeters P, et al. Pharmacokinetics and pharmacodynamics of the dual orexin receptor antagonist daridorexant in Japanese and caucasian subjects. J Clin Psychopharmacol 2020;40:157–66.
Cudeck R. Cudeck R, MacCallum RC. Factor analysis in the year 2004: still spry at 100. Factor Analysis at 100: Historical Developments and Future Directions. Mahwah, NJ: Lawrence Erlbaum; 2007. 01–7.
Paoletti M, Camiciottoli G, Meoni E, et al. Explorative data analysis techniques and unsupervised clustering methods to support clinical assessment of Chronic Obstructive Pulmonary Disease (COPD) phenotypes. J Biomed Inform 2009;42:1013–21.
Feighner JP, Sverdlov L, Nicolau G. Cluster analysis of clinical data to identify subtypes within a study population following treatment with a new pentapeptide antidepressant. Int J Neuropsychopharmacol 2000;3:237–42.
Hirano S, Sun X, Tsumoto S. Comparison of clustering methods for clinical databases. Inf Sci 2004;159:155–65.
Liem-Moolenaar M, Rad M, Zamuner S, et al. Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men. Br J Clin Pharmacol 2011;71:907–16.
Klumpers LE, Fridberg M, de Kam ML, et al. Peripheral selectivity of the novel cannabinoid receptor antagonist TM38837 in healthy subjects. Br J Clin Pharmacol 2013;76:846–57.
Liem-Moolenaar M, de Boer P, Timmers M, et al. Pharmacokinetic-pharmacodynamic relationships of central nervous system effects of scopolamine in healthy subjects. Br J Clin Pharmacol 2011;71:886–98.
Klumpers LE, Roy C, Ferron G, et al. Surinabant, a selective CB(1) antagonist, inhibits THC-induced central nervous system and heart rate effects in humans. Br J Clin Pharmacol 2013;76:65–77.
Baas JM, Mol N, Kenemans JL, et al. Validating a human model for anxiety using startle potentiated by cue and context: the effects of alprazolam, pregabalin, and diphenhydramine. Psychopharmacology (Berl) 2009;205:73–84.
Monti S, Tamayo P, Mesirov J, et al. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach Learn 2013;52:91–118.
Lawrence Erlbaum Associates, Byrne BM. Structural Equation Modeling with EQS: Basic Concepts, Applications and Programming. 2006.
Davidian M, Giltinan DM. Nonlinear models for repeated measurement data: an overview and update. J Agric Biol Environ Stat 2003;8:387–419.
de Vries GJ, Forger NG. Sex differences in the brain: a whole body perspective. Biol Sex Differ 2015;6:15.
Brooks C, Clayton J. Sex/gender influences on the nervous system: basic steps toward clinical progress. J Neurosci Res 2017;95:14–6.
Zagni E, Simoni L, Colombo D. Sex and gender differences in central nervous system-related disorders. Neurosci J 2016;2016:2827090.
